Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma

NEXT STORY
Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
PREV STORY
Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

GENFIT lance The NASH Education Program pour améliorer la connaissance médicale autour de la NASH

GENFIT lance The NASH Education ProgramTM pour améliorer la connaissance médicale autour de la ...

author_avatar
NASDAQ Market News

Publication Authored by Researchers at Selecta Biosciences and the National Cancer Institute in Proceedings of the National Academy of Sciences (PNAS) Discusses Restoration of Anti-Tumor Activity of Recombinant Immunotoxin LMB-100 When Combined with SVP-Rapamycin

Selecta’s Immune Tolerance SVP Platform Also Discussed in Scientific American’s January 2018 Issue WATERTOWN, ...

author_avatar
NASDAQ Market News

ALR Technologies Partners with Centrus Health Clinics to Conduct a Clinical Pilot

author_avatar
NASDAQ Market News